Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC. Homo sapiens

Patients with metastatic colorectal cancer were enrolled for treatment with cetuximab monotherapy. Transcriptional profiling was conducted on RNA from pre-treatment metastatic site biopsies to identify genes whose expression correlates with best clinical responses. Keywords: comparison of disease control group versus non-responder group of patients Overall design: single pre-treatment metastatic biopsy from each patient analyzed